Anaconda Biomed is a Spanish start-up, based in Barcelonawhich is developing a new-generation catheter to efficiently treat stroke.
Recently, it has sold part of its shareholding for €20m.
This makes the deal the second largest in the health sciences sector so far this year.
Medical technology is so important, and so much in the news, that it continues to attract private capital.
Both the sector and its movements in corporate finance give a good account of this.
WHO IS ANACONDA BIOMED?
Anaconda Biomed is one of the world's most innovative medical technology companiesfounded in 2015.
It is currently developing ANCD BRAIN.
It is a novel system of mechanical thrombectomy with catheter used to treat acute ischemic stroke, also known as acute ischemic stroke, also known as acute ischemic stroke. Ictus.
This catheter allows the thrombus causing it to be captured and aspirated.
The system is introduced into the artery, and is able to suspend blood flow and capture the thrombus without leaving any remnants in the patient's circulation.
SECOND MOST IMPORTANT OPERATION
At the beginning of December, sold part of its shares in the company.
It has done so in a round amounting to 20M€making it the second largest deal in the healthcare sector in 2019.
The first was the €72m invested last June in Sanifit Therapeutics.
But as far as the sale that is the subject of this post is concerned, all the investors who had already participated in the previous sale have participated.
Some of them are, for example, Ysios Capital, Banco Sabadell, Innogest, and Omega Funds.
Since its launch, Anaconda Biomed has already raised €40 million.
PRODUCT VALIDATION IN EUROPE AND THE U.S.A.
The €20 million will be used by the firm for a clinical study to validate its product in both the European Medicines Agency (EMA), as in the American Food Drug Administration (FDA).
In total, 125 patients will be recruited, with results expected by the end of the third quarter of next year.
But it's not all plain sailing for the company.
The entry into force of the new medical device regulation in Europe has forced them to change their strategy: more patients in clinical trials and more investment are needed.
MARKET LAUNCH IN 2021
If approved, the new release date is early 2021.
At this point, it is worth noting that in the medical device market, it is common for companies to take the first steps towards commercialisation, followed by licensing or purchase agreements.
Among the multinationals most interested in this medical area are Medtronic, Johnson & Johnson and Stryker, among others.
THROMBECTOMIES AND STROKES
The mechanical thrombectomy market accounted for $720M in revenues in the US last year.
Although it should be taken into account that it is a sector that has been indicated since 2015, and previously it was not included in the medical guidelines.
El Ictus is the leading cause of disability and the second leading cause of death in the world.
OTHER RELEVANT INDUSTRY ROUNDS
PSIOUS
Psious develops virtual reality platform designed to add value to mental health treatment.
It uses hyper-realistic virtual environments to treat anxiety disorders through virtual exposure therapy.
In this way, professionals can improve mental health therapies.
Recently, the company has sold part of its shareholding for 8M€ for their growth.
TAAP WATER
Taap Water provides affordable, clean and sustainable water solutions straight from the tap at home..
The company is based in London, but also operates in Spain.
It has a team of experienced water and technology experts.
In its last round of Series A funding, earlier this year, it was able to raise $2,1M.